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Abstract
Introduction Radiotherapy outcomes might be further improved
by a greater understanding of the individual variations in normal
tissue reactions that determine tolerance. Most published
studies on radiation toxicity have been performed
retrospectively. Our prospective study was launched in 1996 to
measure the in vitro radiosensitivity of peripheral blood
lymphocytes before treatment with radical radiotherapy in
patients with breast cancer, and to assess the early and the late
radiation skin side effects in the same group of patients. We
prospectively recruited consecutive breast cancer patients
receiving radiation therapy after breast surgery. To evaluate
whether early and late side effects of radiotherapy can be
predicted by the assay, a study was conducted of the
association between the results of in vitro radiosensitivity tests
and acute and late adverse radiation effects.
Methods Intrinsic molecular radiosensitivity was measured by
using an initial radiation-induced DNA damage assay on
lymphocytes obtained from breast cancer patients before
radiotherapy. Acute reactions were assessed in 108 of these
patients on the last treatment day. Late morbidity was assessed
after 7 years of follow-up in some of these patients. The
Radiation Therapy Oncology Group (RTOG) morbidity score
system was used for both assessments.
Results Radiosensitivity values obtained using the in vitro test
showed no relation with the acute or late adverse skin reactions
observed. There was no evidence of a relation between acute
and late normal tissue reactions assessed in the same patients.
A positive relation was found between the treatment volume and
both early and late side effects.
Conclusion After radiation treatment, a number of cells
containing major changes can have a long survival and
disappear very slowly, becoming a chronic focus of
immunological system stimulation. This stimulation can produce,
in a stochastic manner, late radiation-related adverse effects of
varying severity. Further research is warranted to identify the
major determinants of normal tissue radiation response to make
it possible to individualize treatments and improve the outcome
of radiotherapy in cancer patients.
Introduction
Ionizing radiation is widely and successfully applied in oncol-
ogy. However, because of dose restrictions, a definitive cure
cannot be achieved for many tumour entities and localizations.
Despite the advanced radiotherapy facilities available, high
doses of radiation still induce early and late skin effects. Unac-
ceptable normal tissue reactions remain the limiting factor for
delivering a tumoricidal dose in radiotherapy. Radiation is an
unusual toxic agent in that the timing of tissue damage expres-
sion can vary widely between one tissue or tumour and
another [1]. On the other hand, recent large-scale trials of
adjuvant radiotherapy for breast cancer showed that the over-
all survival benefit of radiotherapy can be considered an inher-
ent characteristic of the treatment and is not influenced by theBreast Cancer Research    Vol 7 No 5    López et al.
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duration of follow-up [2]. Data in the literature strongly support
a causal relation between better outcomes and improved radi-
otherapeutic techniques [3]. Changes in radiotherapy practice
over the years include recognition of the importance of fraction
size, fraction number, total dose, overall time for both tumour
and normal tissue reactions, and the introduction of conserva-
tive therapy.
Radiotherapy outcomes might be further improved by a
greater understanding of the individual variations in normal tis-
sue reactions that determine tolerance [4]. When accurate
genetic-based or cell-survival-based predictive assays are
available to study tumour and normal tissue radiosensitivity,
radiation therapy will become an exact science [5], allowing
truly individual optimization and the prediction of adverse reac-
tions [6]. It is of great importance to identify the variations in
intrinsic (cellular) radiosensitivity and extrinsic factors that are
associated with a change in the risk of morbidity. It has yet to
be determined whether intrinsic cell radiosensitivity or extrinsic
factors have greater influence on individual differences in dam-
age expression [7-10]. The very high incidence of breast can-
cer in Western countries, partially attributable to the ageing of
their populations, and the increasing use of conservative sur-
gery and postoperative radiotherapy for its treatment make the
above type of study of special interest, with the side effects of
radiotherapy an increasingly important issue. Indeed, after the
sweeping changes in the locoregional treatment of breast can-
cer during the last part of the 20th century, it appears that only
a dwindling minority of patients will undergo mastectomy, at
least in urban areas with a high socioeconomic level [11]. The
widely varied biological characteristics of patients with breast
cancer, evidenced in clinical, pathological, cellular, and molec-
ular studies, are sufficient to explain the diversity of treatments
recommended over the past two decades [12]. Recent years
have seen the introduction of changes from conventional radi-
otherapy at 5 × 1.8 to 2.0 Gy per week to more aggressive
schedules such as unconventional protocols [13] or radioche-
motherapy [11]. The gradually increasing success of cancer
treatments has led to longer patient survival. This also carries
with it the penalty of providing a greater opportunity for late
effects to appear, increasing in severity [14] and affecting the
patient's quality of life [15].
With regard to radiotherapy complications, the known factors
influencing normal tissue responses account for only 30% of
interpatient variability in breast cancer patients under well-con-
trolled conditions, leading to the hypothesis that most of the
variability in the severity of these complications is due to differ-
ences in cellular radiosensitivity determined by genetic or epi-
genetic mechanisms [7,10]. Identification of the causes of this
variability in radiation sensitivity could have important implica-
tions for cancer therapy. Evidence of a possible genetic basis
for these differences has been provided by reports of
increased cellular and tissue radiosensitivity in certain genetic
syndromes [16] and of an association among the relative radi-
osensitivities of different normal cell types in the same individ-
ual [17]; this evidence also verifies that cellular radiosensitivity
may be related to tissue response. Current radiobiological
research efforts are aimed at identifying patients with abnor-
mal radiosensitivity at risk for acute and late adverse effects of
radiotherapy treatment [18,19] and detecting molecules that
increase the antitumour effects of radiotherapy [20].
Most published studies on radiation toxicity were performed
retrospectively. This prospective study was launched in 1996
to measure the in vitro radiosensitivity of peripheral blood lym-
phocytes before treatment with radical radiotherapy in patients
with breast cancer, and to assess the early and the late side
effects of radiation on skin in the same group of patients. We
prospectively recruited consecutive breast cancer patients
receiving radiation therapy after breast surgery. To evaluate
whether early and late side effects of radiotherapy can be pre-
dicted by the assay, a study was conducted of the association
between the results of in vitro radiosensitivity tests and acute
and late adverse effects of radiation.
Materials and methods
Patients
The data analysed in this study were derived from 108 consec-
utive breast cancer patients who received radiotherapy and
were followed up for 7 years within our departmental program
for the predictive testing of the radiosensitivity of normal tis-
sue. The investigation was approved by the local ethics com-
mittee, and written, informed consent was obtained from all
patients. Patient recruitment started in March 1996. Late
adverse skin effects were measured between December
2003 and June 2004. The study design and patient and treat-
ment characteristics have been published previously [9].
The patients were treated with postoperative radiation therapy
after mastectomy (54 patients) or with breast-conserving ther-
apy using a standardized 60Co technique (54 patients). The
dose delivered was 50 Gy over a period of 5 weeks, in daily
fractions of 2 Gy (25 fractions at 5 per week). External radia-
tion was delivered by the cobalt unit in almost all of the
patients (98%), and only 2% received irradiation from a Linac
6-MV x-ray linear accelerator. The whole breast or chest wall
was irradiated by two parallel, opposed tangential fields, with
wedges used to correct dose inhomogeneities. The dose was
prescribed at the ICRU (International Commission on Radia-
tion Units and Measurements) point at the midline of the cen-
tral axis. Dose homogeneity was more than 85% in the majority
of the cases. Patient treatments were planned using com-
puted tomography images and a conventional simulator. To
administer regional nodal radiation, we used a direct anterior
field to irradiate internal mammary nodes. Supraclavicular and
axillary lymph node areas were treated by irradiation of the axil-
lary–supraclavicular field and the posterior axillary field. The
total dose was calculated at 3 cm in the supraclavicular area
and at the midplane in the axilla. The conservatively treatedAvailable online http://breast-cancer-research.com/content/7/5/R690
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patients also received a tumour bed boost of 16 to 25 Gy
using an iridium implant (192Ir), always 15 days after external
radiotherapy or electron beam therapy. The 192Ir implants were
done in accordance with the rules of the Paris System of
Dosimetry. The dose was calculated at the reference isodose,
defined as 85% of the basal dose calculated in the central
plane of application. The total dose delivered by 9-to 12-MeV
electron beams was 16 Gy at 2 Gy per fraction. The dose was
prescribed to the 90% isodose line. A bolus was sometimes
used to optimize the homogeneity of dose distribution.
All medical records of these 108 patients were available and
were reviewed. Patient files included details of surgery, clini-
cal-pathological stage, adjuvant treatment, and the subse-
quent follow-up. The records also included full details of the
radiotherapy treatment, and a photograph of the irradiated
field was always made on the last treatment day to record the
intensity of the acute radiation-induced injury on the skin of
each patient.
Definitions of descriptive terms for skin reactions
The severity of skin reactions was assessed by means of a sim-
ple scale (Table 1), using scores based on the absolute side-
effect scale proposed by the Radiation Therapy Oncology
Group/European Organization for Research and Treatment of
Cancer [9], adapted here to the nomenclature proposed by
Burnet and colleagues [4] in order to facilitate communication
among groups studying normal tissue radiosensitivity. The
term 'normal range' refers herein to the range of normal tissue
reactions observed in typical radiotherapeutic clinics that treat
large numbers of patients without genetic syndromes. All of
the skin reactions observed in our study fell within the normal
range, and no over-reactors were found.
Radiosensitivity assay
Initial radiation-induced DNA damage in peripheral blood lym-
phocytes was measured as described elsewhere [17,18] and
was considered an indicator of the molecular radiosensitivity
of the normal cells studied. Early and late skin side effects
were assessed as mentioned above.
Early side-effect data
The unit of analysis was a group of 108 patients treated with
radiotherapy for curative purposes after breast surgery. The
most frequent acute complications found were erythema
(91.7%), dry desquamation (29.6%), and moist desquamation
(35.2%). According to the score system summarized in Table
1, approximately 13% of patients were classified as highly
radiosensitive. Early side effects on the skin might be consid-
ered an indicator of clinical radiation sensitivity, and their inten-
sity, score, and distribution have been previously described
[9].
Late side-effect data
Although a significant proportion of the variation in response
of normal tissues could be attributed to treatment-related fac-
tors, our results showed that dose effects were not sufficient
to explain the differences between patients in their skin
response (data not shown). Our team previously reported an
adequate correlation between scoring of radiation-induced
acute skin effects by direct observation and scoring after
examination of photographic images, supporting the accuracy
of the direct observation of lesions of normal tissue. Therefore,
this direct-observation method was used for the assessment
of late normal tissue changes in the 60 patients studied, as fol-
lows: on the day programmed for the late follow-up, a single
physician (EL) generated a report based on direct clinical
observation of the whole treated skin, scoring the degree of
reaction on the scale used (Table 1, Fig. 1).
Comparison of in vitro and in vivo results
A two-sided Student's t-test was used to compare mean val-
ues of initial radiation-induced DNA damage between the
patient groups. Contingency tables and the χ 2 test were used
to assess any relation between early and late effects.
Table 1
Scoring system used to document cutaneous and subcutaneous reactions in breast cancer patients receiving radiotherapy
Grade Early reactionsa Late reactionsb
Grade 0 – Highly radioresistant patients No toxicity observed: no erythema, desquamation, or 
pain
Absence of differences between irradiated and 
nonirradiated skin
Grade 1 – Moderately radioresistant patients Faint, dull, or bright erythema, psilosis, dry 
desquamation, mild oedema
Minimal telangiectasia, slight breast asymmetry, mild 
hyperpigmentation
Grade 2 – Patients with average radiosensitivity Severe erythema, at least one moist desquamation of 
small size, moderate oedema
Marked telangiectasia, moderate hyperpigmentation, 
increased density and palpable firmness, mild oedema
Grade 3 – Moderately radiosensitive patients Severe or confluent moist desquamation Partially confluent telangiectasia, severe 
hyperpigmentation, severe oedema, subcutaneous 
fibrosis with fixation
Grade 4 – Highly radiosensitive patients Ulceration, haemorrhage Totally confluent telangiectasia, very marked density, 
retraction and fixation. Major aesthetic sequelae in 
treated breast
aMorbidity assessed at the end of radiotherapy treatment. bMorbidity assessed at end of 7-year follow-up periodBreast Cancer Research    Vol 7 No 5    López et al.
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The relations between in vivo and in vitro results were studied
using a nonparametric regression test, and Spearman's ρ  cor-
relation coefficient was calculated. The Statistical Package for
Social Sciences (SPSS 11.5) was used for all data process-
ing. Graphics and basic biostatistics were obtained using
Graphpad (GraphPad Software Inc, San Diego, CA, USA).
Results
Radiosensitivity test
Initial radiation-induced DNA damage was determined in lym-
phocytes from 108 breast cancer patients after γ -irradiation.
The parameter selected was the estimated number of dbs per
Gy and per DNA unit [21]. It should be noted that the results
obtained from the reference sample of patients included in this
paper matched the results obtained in lymphocytes from other
breast cancer patients analysed at our laboratory in ongoing
studies. [6]. The mean value ± the standard error of the mean
was 1.83 ± 0.18 double-strand breaks per Gy.
Early radiation-induced injury
Assessment of clinical radiation sensitivity was based on the
acute skin reactions to the radiotherapy measured [9] on the
last day of treatment. Five patients (4.6%) with no adverse side
effects were classified as highly radioresistant; 36 (33.3%),
44 (40.7%), and 10 patients (9.3%) with mild to moderate skin
reactions were classified as, respectively, moderately radiore-
sistant, average, and moderately radiosensitive; and 13
patients (12%) with pronounced signs of radiation acute sen-
sitivity were considered highly radiosensitive (Fig. 1). The cor-
respondence between the descriptive terms and the radiation
sensitivity data is summarized in Table 1. Acute effects on the
skin included in the treatment field, such as erythema or desq-
uamation, normally resolve rapidly in most patients. Individual
variation in the level of normal tissue response could be theo-
retically interpreted by the classical sigmoid dose–response
curve. Comparison of collateral effects between the surgical
treatment subgroups (mastectomy versus breast-conserving
therapy) showed that radiation-induced acute toxicity on the
skin of the breast cancer patients has the same frequency and
intensity regardless of the surgical approach, even when the
use of concurrent chemotherapy was taken into consideration
[9].
Overall survival and actuarial probabilities of normal 
tissue sequelae
Data of survival and late morbidity records were obtained for
87 patients who had undergone radiotherapy treatment for >7
years, of whom 51 were free of cancer disease; 9 were living
with disease, 22 had died, and 5 who had received recon-
structive surgery were not assessed. A total of 21 patients
were missing from the follow-up. Seven years after treatment,
the actuarial overall survival of the whole series of breast can-
cer patients was 48.84 ± 7.62% (mean ± standard error of the
mean).
The actuarial probabilities of late radiation side effects,
expressed as percentages ± standard errors of the mean,
were 10.19 ± 2.91 for highly radioresistant; 10.19 ± 2.91 for
moderately radioresistant, 21.30 ± 3.94 for average, 12.96 ±
3.23 for moderately radiosensitive, and 0.0 for highly radiosen-
sitive. Fig. 1 depicts the distribution of the frequency of acute
and late effects according to the severity. The distributions of
the severity of early and late effects differed. Statistical com-
parison between early and late collateral effects in the same
group of patients gave a χ 2 value of 22.38 (P = 0.0002), dem-
onstrating a very different distribution frequency between radi-
ation-induced acute toxicity and radiation-related late
morbidity.
Correlation between radiobiological test and early 
radiation skin side effects
The distribution of early normal tissue reactions observed in
this study could be considered approximately normal in shape
(Fig. 1). The distribution of the lymphocyte radiosensitivity
measured  in vitro could also be considered approximately
Gaussian [6,18]. This similarity prompted us to examine
whether the same relation could be found between the
number of initial radiation-induced DNA double-strand breaks
and the severity of acute adverse skin effects. No relation was
found (Fig. 2) between the molecular radiosensitivity values in
lymphocytes and the early normal tissue reactions observed in
vivo (Spearman ρ  = 0.076; 95% confidence interval, -0.149 to
0.293; two-tailed P = 0.497).
Figure 1
Frequency distribution of skin reactions in women with breast cancer  treated postoperatively with radiotherapy Frequency distribution of skin reactions in women with breast cancer 
treated postoperatively with radiotherapy. Reactions were classified as 
early (if observed at the end of the radiotherapy, 108 women) or late (if 
observed at the 7-year follow-up, 60 women). X-axis Radiation Therapy 
Oncology Group scoring system modified using the terminology pro-
posed by Burnet (4): A, average; HRR, highly radioresistant; HRS, 
highly radiosensitive; MRR, moderately radioresistant; MRS, moderately 
radiosensitive.Available online http://breast-cancer-research.com/content/7/5/R690
R694
Correlation between radiobiological test and late 
radiation skin side effects
The distribution of late adverse effects observed in these
patients does not appear to fit a Gaussian distribution (Fig. 1),
and no statistical relation was found between the radiosensi-
tivity test results and the late effects assessed (Fig. 3). No sig-
nificant relation was found between the in vitro assay results
and the severity of late side effects (Spearman ρ  = 0.063;
95% confidence interval, -0.219 to 0.335; two-tailed P  =
0.655). Considering the patients with tolerable late effects
(highly or moderately radioresistant or with average radiore-
sistance) separately from those with more severe effects
(moderately or highly radiosensitive) in a scatter plot, it
appears (Fig. 4) that the molecular radiosensitivity assay did
not distinguish patients at different levels of risk of developing
more severe late skin reactions after radiotherapy treatment.
Correlation between early and late skin effects
The data on the severity of early and late adverse effects after
radiotherapy for breast cancer showed no relation between
these toxic effects (Fig. 5). According to our results, acute and
late radiation-related morbidities are independent adverse
effects, (Spearman ρ  = 0.032; 95% confidence interval, -
0.233 to 0.293; two-tailed P = 0.809).
Correlation between early and late effects and treatment 
volume
It has classically been reported that patient skin tolerance may
be lower with larger breast size. In the present study, this rela-
tion was studied in a group of patients treated with breast-con-
serving surgery, estimating the breast volume from the bra
size. When acute adverse effects were considered in 47
patients, a positive relation was found (Spearman ρ  = 0.497;
95% confidence interval, 0.236 to 0.691; two-tailed P  <
0.001) (Fig. 6). However, the relation was weaker when late
side effects were considered (Spearman ρ  = 0.423; 95% con-
fidence interval, 0.070 to 0.682; two-tailed P = 0.018), per-
haps because of the smaller number of cases (n  = 31)
analysed (Fig. 7).
Figure 2
Relation between severity of early radiotherapy-induced skin morbidity  and lymphocyte molecular radiosensitivity Relation between severity of early radiotherapy-induced skin morbidity 
and lymphocyte molecular radiosensitivity. Skin morbidity in 108 
women was assessed on the treated skin using the scoring system 
summarized in Table 1. Lymphocyte molecular radiosensitivity was 
measured as DNA double-strand breaks (dsb) by dose unit (Gy) and 
DNA unit (200 Mbp). bp, base pairs.
Figure 3
Relation between severity of late radiotherapy-induced skin morbidity  and lymphocyte molecular radiosensitivity Relation between severity of late radiotherapy-induced skin morbidity 
and lymphocyte molecular radiosensitivity. Skin morbidity in 60 women 
was assessed on the treated skin using the scoring system summarized 
in Table 1. Lymphocyte molecular radiosensitivity was measured as 
DNA double-strand breaks (dsb) by dose unit (Gy) and DNA unit (200 
Mbp). bp, base pairs.
Figure 4
Scatter-plot of quantified late skin reactions of patients and the corre- sponding in vitro radiosensitivity values Scatter-plot of quantified late skin reactions of patients and the corre-
sponding in vitro radiosensitivity values. Horizontal solid lines are the 
mean values for each group of patients with breast cancer. Moderate (n 
= 38), women with reactions scored as highly or moderately radiore-
sistant or as having an average response; severe (n = 12), patients with 
reactions scored as highly radiosensitive.Breast Cancer Research    Vol 7 No 5    López et al.
R695
Discussion
In this study, early and late complications in normal tissue were
assessed at an arbitrary single point. In this situation, a relative
scale of normal tissue reactions, such as the score system pro-
posed by Burnet [4], has a number of advantages over an
absolute one. The main objectives of our study were to identify
patients with extreme reactions within the normal range and to
compare the results of an in vitro radiosensitivity test with the
severity of acute and late reactions in the same patients. By
using this relative scale, we were able to meet these objec-
tives. The concept of the predictive testing of normal tissue
reactions in order to individualize radiotherapy prescriptions is
founded on a hypothetical relation between the radiosensitivity
of cells and that of normal tissue. Although we are inclined to
support this hypothesis, the test applied in the present study,
based on the initial radiation-induced DNA damage, proved
inadequate for use in the individualization of radiotherapy
therapy.
Early effects such as erythema and desquamation usually
appear during or immediately after radiotherapy therapy,
whereas late effects develop some years afterwards. The
acute side effects resolve rapidly without treatment [11]. How-
ever, in a substantial group of patients, radiation-induced
fibrosis, telangiectasia, and skin pigmentation disorders
appear at different times after radiotherapy. Generally, the
course of radiation sequelae follows a distinct clinical pattern.
An erythematous rash can develop on the skin of treated
patients within a few hours of exposure and can persist or
slowly worsen until the end of radiotherapy treatment. This sit-
uation is transient in nature. In severe cases, subepidermal
blisters and ulcers may develop. Most of the injuries heal,
although the expression of radiation-induced effects can reap-
pear in some individuals after a latency period. Late damage
becomes more severe, progresses with time, and usually can-
not be halted or reversed [22]. The inability to predict the
length of the latency period creates a major problem for the
management of these patients. A better understanding of indi-
vidual variations in normal tissue reactions, which determine
tolerance, may allow the individualization of radiotherapeutic
prescriptions and improve outcomes. The lag time to the onset
of initial late effects might be expected to yield information on
the mechanisms underlying the development of late radiation
sequelae. Extreme side effects of radiotherapy, including an
increased cancer risk after radiation, were observed in
patients with inherited disorders such as ataxia-telangiectasia
and Nijmegen syndrome [16]. According to the present
results, there appears to be no mechanistic relation between
the early and late adverse effects of radiation treatment. We
speculate that these differences may arise because the heal-
ing of acute injuries is a deterministic process whereas late
side effects may be stochastic phenomena.
Unconventional, more aggressive irradiation protocols are
usually associated with an aggravation of acute reactions that
might be related to more severe late effects. Therefore, amel-
ioration of the acute response to radiation has been proposed
as a useful approach to minimize late side effects of effective
radiation therapy. This proposal assumes a relation between
acute and late effects via a non-healing acute response com-
ponent that directly progresses to a late effect [23]. However,
the present results do not support the hypothesis that late
effects in normal tissue can be predicted from the acute reac-
tions observed in the same patients.
Figure 5
Relation between the severity of early and late side effects of radiother- apy for breast cancer Relation between the severity of early and late side effects of radiother-
apy for breast cancer. Women with breast cancer (n = 60) were 
treated postoperatively with radiotherapy and assessed using the scor-
ing system summarized in Table 1.
Figure 6
Relation between estimated irradiation volumes and severity of early  effects of radiotherapy for breast cancer Relation between estimated irradiation volumes and severity of early 
effects of radiotherapy for breast cancer. Irradiation volumes were esti-
mated from the women's bra size, and the severity of the early effects 
were scored in the same women (n = 50). Dotted line shows the corre-
sponding regression line (P < 0.001).Available online http://breast-cancer-research.com/content/7/5/R690
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It also proved impossible in the present study to predict acute
or late effects from the results of an in vitro assay to measure
initial radiation-induced DNA damage. Until recently, it has
been generally accepted that the genotoxic consequences of
radiation exposure derive from the damage inflicted directly by
radiation, producing irreversible changes during DNA replica-
tion or cell division or during the processing of DNA damage
by enzymatic repair processes [24]. However, there is now
considerable evidence that cells that are the progeny of
exposed cells but that are not themselves exposed may divide,
express delayed gene mutations, and carry chromosomal
aberrations. This effect, known as radiation-induced genomic
instability, may be expressed via delayed lethal mutations [25],
causing prolonged perturbation of tissue volume within the
radiation field [26]. Although the mechanisms of those delayed
effects of ionizing radiation are unclear, excessive production
of reactive oxygen species has been implicated [27]. Recent
experiments showed that macrophage activation and neu-
trophil infiltration are consequences of the recognition and
clearance of radiation-induced apoptotic cells and that
increased phagocytic cell activity persists after removal of
apoptotic bodies. It was demonstrated, contrary to expecta-
tions, that the recognition and clearance of apoptotic cells
after exposure to radiation produces persistent macrophage
activation and a genotype-dependent inflammatory-type
response [28]. These phenomena and radiation-induced
genetic changes may be important determinants of the longer-
term consequences of radiation exposure [28]. Moreover, new
evidence suggests that cytokine-mediated multicellular inter-
actions initiate and sustain the fibrogenic process [29,30] that
is a long-term effect of radiotherapy.
Initial DNA damage and post-radiation cell survival after radia-
tion have been directly related in in vitro experiments [31]. The
present findings indicated that the level of radiation-induced
DNA damage in normal cells was not a major determinant of
the severity of early skin injury. Moreover, no relation was found
between the acute injuries and the late sequelae that, after an
undetermined latency period, became a burden, lessening the
quality of life of these patients [32].
However, a significant correlation has been demonstrated,
using new methodologies, between five single-nucleotide
polymorphisms (SNPs) and the risk of radiation-induced nor-
mal tissue reactions in a small group of breast cancer patients
[33]. In fact, the completion of the human genome project and
the availability of novel and powerful technologies in genom-
ics, proteomics, and functional genomics promise to have a
major impact on clinical practice. These developments are
likely to change the way in which diseases will be diagnosed,
treated, and monitored in the near future. Cancer, as a com-
plex disease that affects a significant proportion of world
population, has become a prime target of novel technologies,
often referred to as 'omic' platforms, and it is anticipated that
progress will be made towards a predictive, individualized
approach to cancer care. One area of knowledge where
advances are expected is on the complex variability in normal
tissue radiation response, which depends on the interaction of
multiple gene products. There is a growing shift from the study
of single parameters of molecular or cellular radiosensitivity to
the analysis of complex biological systems, and one of the
main challenges we face is how best to apply the 'omic' tech-
nologies to clinically relevant samples in a well-defined clinical
and pathological framework. An example of this type of venture
is the European GENEPI project [34], which aims to study a
large cohort of patients under highly controlled and standard-
ized radiotherapy conditions.
Conclusion
Our first conclusion is an experimental one. These results do
not support the hypothesis that the response of normal tissue
to radiation can be predicted by an in vitro test. This conclu-
sion was reached by other authors [8,10], although some
results in defence of this hypothesis have also been published
[35,36]. A possible explanation is that in vitro cellular radio-
sensitivity tests and molecular DNA damage assays do not
take account of the variable degree of cytokine response, tis-
sue remodeling, and collagen deposition that may characterize
the specific normal-tissue response of each patient [29]. The
paradigm that radiotherapy effects are restricted to the direct
or indirect effects of radiation-induced DNA damage is
challenged by the present results, which indicate that early
and late effects can also be induced by unexpected interac-
tions between irradiated and nonirradiated cells (bystander
effects). This conclusion is supported by published results that
showed a clear relation between the severity of late toxicity in
radiotherapy treatment and the volume of normal tissue
Figure 7
Relation between estimated irradiation volumes and severity of late  effects of radiotherapy for breast cancer Relation between estimated irradiation volumes and severity of late 
effects of radiotherapy for breast cancer. Irradiation volumes were esti-
mated from the women's bra size, and the late effects were scored in 
the same women (n = 33). Dotted line shows the corresponding 
regression line (P = 0.018).Breast Cancer Research    Vol 7 No 5    López et al.
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included in the field of treatment, although a significant corre-
lation was found between breast size and dose
inhomogeneities that may account for the marked changes in
breast appearance reported in women with large breasts [37].
Our second conclusion is a theoretical one, and takes the form
of a proposal to change the model adopted in radiobiological
studies to date. Thus, for teaching and research purposes,
'direct action' could be defined as all physicochemical proc-
esses that occur after energy cession from the ionizing radia-
tion to the tissues. Within this concept would be included
actions produced by free radicals that result from the interac-
tion of radiation with the water molecules – that is, the effects
hitherto designated indirect radiation action on the DNA mol-
ecule. The cellular consequences of the direct action of radia-
tion in terms of lethal and potentially lethal damage to DNA can
be explained by linear-quadratic radiation cell survival models.
However, these models cannot explain the late adverse effects
of radiation, and a more general theory appears to be required.
A few days after the end of radiation treatment, cells within the
irradiated volume can act in one of three ways: they can grow
and divide, the basis for the healing of acute injuries; they can
not grow but stay alive; or they may survive for a long time with
important immunological changes, disappearing by apoptosis
or apoptosis-like cell death very slowly and becoming a
chronic focus of immunological system stimulation that could
produce the late actions observed. Therefore, indirect action
could be considered the whole immunological response of the
body to the stress induced by radiation in the target volume.
This may produce late side effects of varying severity that in a
stochastic fashion, through a time-dependent probability rela-
tion, could lead to a lifelong risk of developing late complica-
tions [14,32,38]. In this relation, the volume of tissue irradiated
may be a multiplicity constant of the frequency and severity of
the late side effects. Patients and clinicians should be aware
of these aspects of radiotherapy therapy. The study of these
immunological changes is complex but could, given the human
genome data now available, offer a key to improving radiother-
apy outcomes in cancer patients.
Finally, our group supports the view that the risks of radiother-
apy can be fully understood only after long-term follow-up
studies. An important research aim is to develop a test that can
predict late side effects.
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